Log in to search using one of your social media accounts:

 

Longer Progression - Free Survival for Durvalumab in NSCLC

Longer median progression - free survival from randomization, higher response rate with durvalumab
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Internal Medicine, Oncology, Pathology, Pharmacy, Pulmonology, Radiology, Surgery, Conference News, Source Type: news

Related Links:

Conditions:   Non Small Cell Lung Cancer;   NSCLC;   NSCLC, Stage IIIB;   NSCLC Stage IV Interventions:   Drug: Pembrolizumab;   Radiation: Sterotactic Body Radiotherapy Sponsors:   Royal Marsden NHS Foundation Trust;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we tried to identify and validate lung cancer driver genes to facilitate the diagnosis and individualized treatment of patients with this disease. To analyze distinct gene profile in lung cancer, the RNA sequencing data from TCGA and microarray data from Gene Expression Omnibus were used. Then, shRNA-pooled screen data and CRISPR-Cas9-based screen data in lung cancer cells were used to validate the functional roles of identified genes. We found that thousands of gene expression patterns are altered in lung cancer, and genomic alterations contribute to the dysregulation of these genes. Furthermore, we identif...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Review Articles Source Type: research
Authors: Kim C, Giaccone G Abstract INTRODUCTION: The mitogen-activated protein kinase (MAPK) pathway is intimately implicated in the molecular pathogenesis of non-small-cell lung cancer (NSCLC). Aberrant MAPK signaling resulting from the upstream activating mutations converges on mitogen-activated protein kinase kinase 1/2 (MEK1/2), making MEK inhibition an attractive strategy for the treatment of NSCLC. Several MEK inhibitors have demonstrated anticancer activity in patients with NSCLC. Areas covered: In this article, we discuss the biological rationale for the use of MEK inhibitors and summarize the clinical exp...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Abstract BackgroundEpidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer (NSCLC) is a subgroup of oncogene addicted lung cancer that predicts response to tyrosine kinase inhibitors (TKI). However, there is variability in response and survival outcomes in patients with EGFR mutation treated with TKI. AimTo describe clinical characteristics, treatment patterns and factors influencing outcomes in patients with EGFR‐mutated NSCLC in South Western Sydney Local Health District. MethodsRetrospective review of patients with EGFR‐mutated NSCLC diagnosed between January 2010 and June 2016. ResultsA tot...
Source: Internal Medicine Journal - Category: Internal Medicine Authors: Tags: Original Article Source Type: research
The incidence of thromboembolic events, ranging from deep vein thrombosis to disseminated intravascular coagulation (DIC), is assumed to be 7-fold higher in patients with cancer as compared to incidence in the overall population and is greater within the first months after diagnosis [1]. Importantly, cancer patients with venous thromboembolism (VTE) have an increased risk of early mortality during chemotherapy, elevated risk of disease progression and shortened survival [2]. In patients with non-small cell lung cancer (NSCLC), the incidence of VTE has been estimated to be up to 14% throughout the course of the disease, whi...
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
Dr. Jack West reviews data on the FDA-approved combination of dabrafenib/trametinib for patients with BRAF V600E mutation-positive advanced NSCLC, as published by Planchard & colleagues in Lancet ... Author: BeaconMedIC Added: 12/08/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Condition:   Brain Metastases Intervention:   Radiation: WBRT with hippocampus-sparing and SIB Sponsors:   Samsung Medical Center;   Korean Radiation Oncology Group Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Non-small Cell Lung Cancer Intervention:   Biological: Pemetrexed and donor-derived NK cell infusion Sponsors:   Asan Medical Center;   Korea Research Institute of Bioscience and Biotechnology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Non-Squamous Non-Small Cell Lung Carcinoma;   Stage I Non-Small Cell Lung Cancer AJCC v7;   Stage IA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Smal l Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stag...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Brain Metastases Intervention:   Radiation: WBRT with hippocampus-sparing and SIB Sponsors:   Samsung Medical Center;   Korean Radiation Oncology Group Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Conferences | Internal Medicine | Non-Small Cell Lung Cancer | Pathology | Radiology | Respiratory Medicine